Latest Kura Oncology News & Updates
See the latest news and media coverage for Kura Oncology. We track all announcements, press releases, and industry mentions in real time, all in one place.
Precision oncology therapeutics developer
kuraoncology.com- Headquarters
- San Diego, United States
- Founded year
- 2014
- Company type
- Public company
- Number of employees
- 300–500
Latest news about Kura Oncology
Company announcements
-
Kura Oncology initiates Japanese Phase 2 trial of ziftomenib
Kyowa Kirin doses first patient in registrational trial for R/R NPM1-m AML. Plans regulatory filing post-trial. Ziftomenib FDA-approved in US as KOMZIFTI.
-
Kura Oncology reports darlifarnib plus cabozantinib activity in ccRCC patients
Subset analysis shows 44% ORR, 94% DCR in cabozantinib-pretreated patients. Tumor shrinkage in 75%. Manageable safety profile. Data from FIT-001 trial presented at IKCS Europe.
-
Kura Oncology presents darlifarnib plus cabozantinib data
Data from FIT-001 trial in ccRCC patients will be presented at IKCS Europe 2026 on April 17. Builds on ESMO 2025 findings.
-
Kura Oncology reports Q4 and full year 2025 financial results
KOMZIFTI generates $2.1M revenue; cash at $667.2M; multiple 2026 clinical milestones planned. Net loss $81M.
Media coverage
-
KURA Kura Oncology reports wider than expected Q4 2025 loss as shares rise modes...
Our platform provides morning reports, sector updates, earnings previews, and market outlook analysis. Stay ahead of the market with daily insights from our expert team...
-
Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML
Kyowa Kirin and Kura Oncology have begun a Japanese Phase II registrational study of ziftomenib in adult patients with r/r NPM1-mutated AML.
-
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Ziftomenib was approved by the U.S. Food and Drug Administration (FDA) in November 2025 for the treatment of adult patients with R/R NPM1 -m AML...
-
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in...
Track Kura Oncology and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Kura Oncology competitors & trending companies
Browse news for competitors to Kura Oncology and other trending companies.
Alligator Bioscience
OrphAI Therapeutics
Medivir
Active Biotech
Oncopeptides
Isofol Medical
Sprint Bioscience
BioInvent
Candel Therapeutics
Blueprint Medicines
Immutep
Imugene
Aura Biosciences
Ascelia Pharma
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS